Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

3100 has been generally well tolerated, with

no reports of serious adverse events deemed related to the drug.

-- Approximately 120 patients have been enrolled in the trial with

enrollment completed at doses up to 360 mg/day. A total of 73 patients

in the three lowest expanded dose groups (60, 150, and 240 mg/day) have

been followed for more than 24 weeks. Of these 73 patients, 31

patients (42 percent) have received MDV3100 for greater than 24 weeks.

Dose escalation in the trial is continuing; the 360 mg/day expansion

group is completely enrolled, dose escalation is in progress at 480

mg/day, and initial dosing at 600 mg/day has started. Thus far a

maximum tolerated dose (MTD) has not been reached.

-- Medivation expects to seek FDA agreement to begin a pivotal Phase 3

registration study in castration-resistant prostate cancer patients in

2009.

Third Quarter 2008 Financial Results

Medivation reported a net loss for the quarter ended September 30, 2008 of $20.5 million, or $0.68 per share, compared with a net loss of $9.4 million, or $0.34 per share, for the same period in 2007. For the nine months ended September 30, 2008, the net loss was $54.5 million, or $1.86 per share, compared with a net loss of $22.2 million, or $0.80 per share, for the same period in 2007.

Total operating expenses for the nine months ended September 30, 2008 were $20.6 million, compared with $9.8 million for the same period in 2007. The increase in operating expenses for the third quarter of 2008 compared with the same period in 2007 is primarily due to increased development costs associated with Dimebon and MDV3100.

For the nine months ended September 30, 2008, total operating expenses were $55.3 million, compared with total operating expenses of $23.7 million for the same period in 2007. These figures include non-cash stock-based compensation expense
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... MILLBROOK, N.Y. , Dec. 18, 2014 Egenix, ... has been elected Chairman of the Board, to succeed ... President and CEO, but will continue as a member of ... that he has added to the company over almost twenty ... The Board of Directors has established a Search ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... Calif., July 7, 2011 InterMune (NASDAQ: ... in ASCEND, a new Phase 3 study of pirfenidone ...  ASCEND is a multinational, randomized, double-blind, placebo controlled Phase ... of Esbriet® (pirfenidone) in IPF patients with mild to ...
... America, Inc . ( www.cordblood-america.com ) (OTC Bulletin Board: ... preservation company focused on bringing the life saving potential ... today that CorCell, its domestic brand for cord blood stem ... Rewards Program in the U.S. for the collection of a ...
... a.m. EDT, the space shuttle Atlantis will streak skyward from ... mission. While the STS-135 flight marks the end of the ... new era of research into infectious diseases, thanks to space ... III, along with their colleagues at Arizona State University,s Biodesign ...
Cached Biology Technology:InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF 2InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF 3InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF 4InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF 5CorCell, a Cord Blood America Company, Launches Referral Rewards Program 2Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 2Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 3Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 4
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Munich, Germany March 2, 2009 >> Genomatix Software, ... of Next Generation Sequencing (NGS) data, announced today that ... Genomatix Mining Station and a Genomatix Genome Analyzer at ... deliver the only complete and integrated analysis solution for ...
... An international team of scientists, led by Monash University ... kills elderly hospital patients worldwide - a discovery that ... systems billions of dollars each year. The research ... , unravelled ways to genetically modify the bacterium ...
... a picky preschooler who,s avoiding their vegetables? A new Cornell ... like X-Ray Vision Carrots and Tomato Bursts left preschoolers ... carrots called "X-ray Vision Carrots" ate nearly twice as much ... simply labeled as "carrots." The Robert Wood Johnson-funded study also ...
Cached Biology News:Boehringer Ingelheim uses Genomatix' Next Generation Sequencing data analysis systems 2Monash scientists debug superbug 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
... histochemically detect specific senescence ... in cultured cells and ... marker is only present ... found in presenescent/quiescent/immortal cells. ...
TAR DNA binding protein...
... BL21 Star strains are ... for improved protein yield ... systems (Figure 1). Because ... synthesizes mRNA more rapidly ...
Biology Products: